| 1.5 -0.86 (-36.44%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.65  |
1-year : | 4.58 |
| Resists | First : | 3.13 |
Second : | 3.92 |
| Pivot price | 2.58 |
|||
| Supports | First : | 1.85 |
Second : | 1.53 |
| MAs | MA(5) : | 2.33 |
MA(20) : | 2.72 |
| MA(100) : | 3.39 |
MA(250) : | 11.39 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 2.1  |
D(3) : | 3.7 |
| RSI | RSI(14): 20.1 |
|||
| 52-week | High : | 43.65 | Low : | 1.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TVRD ] has closed below the lower bollinger band by 23.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 5.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.48 - 2.49 | 2.49 - 2.5 |
| Low: | 1.82 - 1.83 | 1.83 - 1.85 |
| Close: | 1.85 - 1.87 | 1.87 - 1.89 |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Thu, 25 Jun 2026
Price to book forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Tue, 23 Jun 2026
TVRD PE Ratio & Valuation, Is TVRD Overvalued - Intellectia AI
Fri, 12 Jun 2026
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - The Globe and Mail
Mon, 08 Jun 2026
This Cerebras Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
Fri, 08 May 2026
Tvardi Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Fri, 08 May 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 34.6 (%) |
| Held by Institutions | 28.9 (%) |
| Shares Short | 436 (K) |
| Shares Short P.Month | 509 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -68.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -6.93 |
| PEG Ratio | 0 |
| Price to Book value | 1.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|